Table 3.
Ongoing and completed clinical trials exploring CpG oligonucleotides.
| No. | Interventions | Conditions | Phase | Status | NCT Number |
|---|---|---|---|---|---|
| 1 | CpG-STAT3 siRNA CAS3/SS3 radiation therapy | Recurrent non-Hodgkin’s lymphoma |
Phase 1 | Recruiting | NCT04995536 |
| 2 | Anti-OX40 antibody BMS 986,178 TLR9 agonist SD-101 | Solid neoplasms | Phase 1 | Active | NCT03831295 |
| 3 | Peptide vaccine GM-CSF TLR9 agonist PF3512676 |
Stage III–IV melanoma | Phase 1 | Completed | NCT00471471 |
| 4 | Synthetic immunostimulatory DNA conjugated to ragweed allergen | Seasonal allergic rhinitis | Phase 2 | Completed | NCT00346086 |
| 5 | CpG-ODN in situ release of tumor antigen by interventional ablation or drug-eluting beads |
Lung cancer, hepatocellular carcinoma, solid tumors | Phase 1 | Recruiting | NCT04952272 |
| 6 | TLR9 agonist MGN1703 | HIV | Phase 1 Phase 2 |
Completed | NCT02443935 |
| 7 | TLR9 agonist GNKG168 | Leukemia | Phase 1 | Terminated | NCT01035216 |
| 8 | CpG-ODN | Glioblastoma | Phase 2 | Completed | NCT00190424 |
| 9 | Na-GST-1/Alhydrogel® CpG 10104 |
Hookworm disease | Phase 1 | Completed | NCT02143518 |
| 10 | 1018 ISS (CpG ODN) irinotecan cetuximab |
Colorectal neoplasms | Phase 1 | Terminated | NCT00403052 |
| 11 | 1018 ISS (CpG ODN) Hepatitis B vaccine (recombinant) |
Hepatitis B | Phase 1 | Completed | NCT00426712 |
| 12 | IMO-2055 (CpG ODN) | Renal cell carcinoma | Phase 2 | Completed | NCT00729053 |